Update on Histological Reporting Changes in Neuroendocrine Neoplasms
نویسندگان
چکیده
منابع مشابه
On the value of Ki-67 in the prognostic grading of pancreatic neuroendocrine neoplasms: an update
In 1983, Gerdes, Schwab, Lemke and Stein reported upon a new monoclonal antibody which was generated by immunizing mice with nuclei of the Hodgkin lymphoma cell line L428. This antibody was found to label nuclei of proliferating cells including tumor cells. In their report the authors therefore concluded that “Ki-67 (a name derived from the city of Kiel where the authors worked, and the number ...
متن کاملCD200 Expression in Neuroendocrine Neoplasms
Objectives CD200 expression has been well studied in hematopoietic malignancies; however, CD200 expression has not been well-characterized in neuroendocrine neoplasms. We examined CD200 expression in 391 neuroendocrine neoplasms from various anatomic sites. Methods Tissue blocks containing pulmonary small cell carcinoma, pulmonary carcinoid, large cell neuroendocrine carcinoma, pancreatic neu...
متن کاملDigestive System Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms.
Mixed neuroendocrine-non-neuroendocrine neoplasms (MiNEN) are a heterogeneous subgroup of rare neoplasms that represent about a third of all poorly differentiated neuroendocrine carcinomas (PDNEC). MiNEN combine a neuroendocrine component, usually a PDNEC, and a non-neuroendocrine component, generally an adenocarcinoma, both accounting for at least 30% of the neoplasm. MiNEN are classified as h...
متن کاملPANCREATIC NEUROENDOCRINE NEOPLASMS (pNENs)
Pancreatic neuroendocrine neoplasms (pNENs) are relatively rare lesions that have been increasing in incidence over the past few decades largely because of the diagnosis of pancreatic incidentalomas on cross-sectional imaging. Most of these tumors are nonfunctioning presenting with symptoms secondary to mass effect, metastatic disease or as incidental findings. Diagnostic workup aims to assess ...
متن کاملImplications of the new histological classification (WHO 2010) for pancreatic neuroendocrine neoplasms.
Pancreatic neuroendocrine tumors (PanNETs) are rare neoplasms with a more favorable prognosis than pancreatic adenocarcinoma. However, up to 60% of patients with PanNETs present with advanced disease or will recur after surgical resection, requiring multimodal therapy to improve clinical outcomes [1]. In 2011, two phase 3, randomized, placebo-controlled trials provided optimism regarding the tr...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Current Oncology Reports
سال: 2021
ISSN: 1523-3790,1534-6269
DOI: 10.1007/s11912-021-01062-6